Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Filings indexed 6,971 across all filing types
Latest filing 2026-05-01 Regulatory Filings
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Regulatory Filings
2026-05-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements
2026-05-01 English
6-K - GSK plc (0001131399) (Filer)
Foreign Filer Report
2026-04-29 English
Director/PDMR Shareholding
Director's Dealing Classification · 90% confidence The document is an RNS “Transaction notification” detailing personal share transactions by PDMRs (persons discharging managerial responsibilities) including names, positions, dates, volumes, and prices. This clearly matches insider share dealings by directors/executives. According to the taxonomy, this is a Director’s Dealing report (Code: DIRS).
2026-04-29 English
6-K - GSK plc (0001131399) (Filer)
Foreign Filer Report
2026-04-29 English
1st Quarter Results
Earnings Release Classification · 92% confidence The document is an RNS ‘Results Announcement’ from GSK PLC detailing Q1 2026 sales, profit, EPS, segment performance, pipeline progress, guidance, dividend, and share buyback, along with a CEO quote and notice of a webcast. It is a press‐release style initial announcement of quarterly financial results (with key highlights and commentary), not a full interim report or statutory filing. Therefore, it corresponds to an Earnings Release. Q1 2026
2026-04-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.